At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Boston based CEO’ operating in the Health Care space. If you think a CEO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Co-Founder & CEO of NuProbe
Yingshuang Chai is a Co-Founder, CEO, and Chairman of the Board of Directors at NuProbe.
Follow Yingshuang Chai:
About NuProbe: An early stage molecular diagnostics company.
CEO of SilverCloud Health
Ken Cahill is the CEO and co-founder of SilverCloud Health with offices in Boston, Dublin, and London. SilverCloud is the world’s leading digital mental health platform. It enables the delivery of clinically validated digital therapeutic care programs that are proven to significantly improve clinical outcomes, increase access & scale while reducing costs of care delivery. SilverCloud’s multi-award winning platform has spun out from 16 years of clinical research with leading academic institutions, including MIT Media Lab. Today, SilverCloud provides customized solutions for over 240 organizations globally to meet the mental health & chronic care needs of their end users/patients. The platform has been profoundly validated through the use of full randomized control trials as well as real-world data from over 250,000 active SilverCloud end users. Prior to founding SilverCloud Health, Ken held senior positions in several multinationals including, Dell, HP, and Gateway. Ken recently received the 2018 MedTech Boston 40 under 40 award.
Follow Ken Cahill:
About SilverCloud Health: SilverCloud Health provides immediate access to evidence-based and supported digital therapies.
Co-Founder and CEO of Liteboxer
Jeffrey Morin is the founder and CEO of Liteboxer.
Follow Jeffrey Morin:
About Liteboxer: Liteboxer is a provider of a digital fitness platform used to provide an engaging full-body boxing workout.
President and Chief Executive Officer of CCL Industries
Geoffrey Martin joined CCL as President of CCL Label in April 2001. In May 2005 he assumed the role of President and COO of CCL Industries and President and Chief Executive Officer in May 2008. He is responsible for all CCL’s operating units including the Label, Avery and Container businesses. Martin is an international business leader with a proven track record in turnarounds, mergers and acquisitions. Prior to joining CCL, he was the Senior Group Vice President, Worldwide Converting Graphic and Specialty Tapes with Avery Dennison.
Follow Geoffrey Martin:
About CCL Industries: CCL is the largest label company in the world and provides innovative solutions.
Co-Founder & CEO of Silicon Therapeutics
Follow Lanny Sun:
About Silicon Therapeutics: Silicon Therapeutics is a fully integrated drug design, research, and development company.
President & Chief Executive Officer of HotSpot Therapeutics
Follow Jonathan Montagu:
About Atlas Venture, HotSpot Therapeutics: HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Founder, CEO & currently Exec Chair of Triplet Therapeutics
Nessan Bermingham is founder and CEO of Triplet Therapeutics, Inc. He is a serial biotech entrepreneur and investor who has founded several companies including Triplet, Korro Bio and Intellia Therapeutics, “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company,” taking the company from concept to IPO and large partnering deals with approximately 200 employees. He has nearly two decades of experience in Life Sciences startups and investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets. As a venture partner at Atlas Venture and managing partner at Omega Funds, he successfully invested in and managed multiple investments across the United States and Europe. Currently he is also a venture partner at Atlas Venture and is Chair of the Board of Directors of F-star and Akrevia Therapeutics. He served as Intellia’s President and CEO from inception until December 2017. Previously he was an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine. He is an avid mountain biker, snowboarder and trail runner. Nessan is co-founder and was previously chief executive officer of Intellia Therapeutics. He led Intellia from seed investment and incubation at Atlas Venture through its IPO and the advancement of its gene editing platform toward clinical development. He has over ten years of experience in life science investing across venture, secondary, and public markets. Previously, Nessan was a partner at Omega Funds and founder of Bio Equity Capital, a healthcare focused special situations firm. Nessan is also co-founder of Tal Medical.
Follow Nessan Bermingham:
About Korro Bio, Triplet Therapeutics: Triplet is developing transformative therapies that treat repeat expansion disorders at their source.
Chief Executive Officer of Blueprint Medicines
Jeff Albers is the chief executive officer of [Blueprint Medicines](https://www.crunchbase.com/organization/blueprint-medicines), a company engaged in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets. He was previously the president of Algeta. Prior to Algeta, he served at Genzyme, where he spent seven years in senior commercial and corporate development positions. Before joining Genzyme, he spent five years as an Attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo. He also has prior experience as a sales representative for Pfizer. Albers holds a bachelor’s degree in marketing from Indiana University and an MBA from Georgetown University.
Follow Jeff Albers:
About Blueprint Medicines: Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.
Co-Founder & Chief Executive Officer of Veritas Genetics
Follow Mirza Cifric:
About Veritas Genetics, YPO: Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer.
Founder & CEO of LifeStory Health Inc
Leading the first-ever discovery research into the clinical utility of menstrual blood, a recent Proof of Principle study resulted in findings of unique signatures specific to menstrual blood. On-going clinical studies aim to develop the diagnostic science further in order to support our preliminary pipeline. Anna’s resourceful leadership style and entrepreneurial experience has lead LifeStory Health, Inc. through remarkable discoveries and growth in a very short time when compared to most bioscience companies. She attributes this to her steadfast passion for and about Women’s Health. A strong advocate for women’s healthcare, Anna’s pioneering vision to map the menstrual blood proteome through a set of resolute, data-leading principles and an award winning scientific methodology has led to biomarker discovery based on precision medicine. Anna guest lectures for several graduate level programs at Northeastern University including data analytics, chemistry, regulatory affairs, and master’s in business administration. She teaches her own class in the Master’s of Biotechnology Program titled “Women’s Health: Driving Innovation and Cultural Change”. Her advocacy for women’s health continues on her podcast, “Setting the Pace”, in which she and her co-host highlight fellow female innovators.
Follow Anna Villarreal:
About CEOWORLD Magazine, LifeStory Health Inc, NEFC, The Doctor Weighs In: LifeStory Health is a biotech company committed to changing the women’s healthcare market through technology, innovation and vocalization.
CEO of Definitive Healthcare
Jason Krantz is Founder & CEO at Definitive Healthcare.
Follow Jason Krantz:
About Definitive Healthcare, Energy Acuity: Definitive Healthcare aims to transform data, analytics and expertise into healthcare commercial intelligence.
Advisor, Former CEO Obagi Medical of TRUINJECT
Follow Steve Carlson:
About : TRUINJECT™ is a software company focused on the innovation, development & commercialization of medical products for the injectable market.
Founder and CEO of WAGZ
Terry Anderton is the founder and CEO of Wagz and a lifelong dog owner. Terry has a long history of building disruptive and forward-thinking technology companies, including Gemr, a social commerce platform; Trunity, a cloud-based textbook company he took public in 2012; and NitroSecurity, a network security developer acquired by Intel in 2011. Terry has also served as a Senior Sales Executive for Cabletron Systems and McAfee. He started his career leading world wide sales and launching the game of Paintball for the inventor of the game.
Follow Terry Anderton:
About WAGZ: Helping humans stay connected to their dogs through the world’s smartest dog collar.
CEO of Triumvirate Environmental
Follow John McQuillan:
About Triumvirate Environmental: Triumvirate Environmental provides enterprise waste management and environmental services to healthcare, education and industrial markets.
CEO of Dana-Farber Cancer Institute
Edward Benz, Jr. M.D. is President and Chief Executive Officer of Dana-Farber Cancer Institute, CEO of Dana-Farber/Partners Cancer Care as well as Principal Investigator and Director of Dana-Farber/Harvard Cancer Care and a member of the Governing Board of Dana-Farber/Children’s Hospital Cancer Center. An internationally recognized hematologist, Benz received his training at Brigham and Women’s Hospital, the National Institutes of Health, and Harvard Medical School. He is board certified in Internal Medicine and Hematology. Benz continues to be an active NIH funded investigator. He has authored over 300 peer reviewed articles, reviews, chapters and abstracts. He is a co-editor of Hematology: Principles and Practice and of the Oxford Textbook of Medicine for which he and his colleagues received the Royal Society of Authors Textbook Award. He is an associate editor of the New England Journal of Medicine. Benz’ accomplishments have been recognized by a number of distinctions, including membership in the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts and Science. He is a past president of the American Society of Hematology, the American Society of Clinical Investigation and the Association of American Cancer Institutes.
Follow Edward Benz:
About Dana-Farber Cancer Institute, Harvard Medical School: Dana-Farber Cancer Institute is a center dedicated to carrying out adult and pediatric cancer treatment activities and advanced research.
Co-Founder & CEO of Allurion Technologies
Shantanu Gaur co-founded Allurion in 2009 during his second year at Harvard Medical School and is our Chief Scientific Officer. A Paul & Daisy Soros Fellow, Shantanu graduated summa cum laude and Phi Beta Kappa from Harvard College with an S.B. in Biology and significant coursework in polymer chemistry. Shantanu graduated from Harvard Medical School in 2013. He grew up in Pittsburgh, Pennsylvania and lives in Cambridge, Massachusetts.
Follow Shantanu Gaur:
About Allurion Technologies, Genetic Alliance: Allurion Technologies develops a medical device for weight loss that can be delivered and removed without surgery or endoscopy.
Founder and CEO of Medallion
Derek Lo Founder and CEO of Medallion. He was previously co-founder and CEO at Py. He earned his bachelor’s degree in computer science and statistics from Yale University.
Follow Derek Lo:
About Hired, Medallion: Medallion provides a network management platform for the healthcare industry.
President, Founder & Chief Executive Officer of RxAdvance
A noted entrepreneur and an innovator of disruptive business solutions, Ravi Ika founded RxAdvance in 2013 and serves as president and chief executive officer of the full service pharmacy benefit management (PBM) company. He launched RxAdvance to lower pharmacy, specialty and avoidable drug-impacted medical costs and achieve better outcomes, quality and compliance in the new era of value-based health care. The RxAdvance platform Mr. Ika created from the ground up, the Collaborative PBM Cloud™, provides comprehensive automated services for all PBM administrative, clinical, specialty management, care stakeholder engagement, and compliance management functions. It does so in a way never before imagined in the PBM industry. The Collaborative PBM Cloud™ combines pharmacy, medical, and lab information to deliver actionable intelligence. Prescribers receive this real time actionable intelligence at the point of care, pharmacists at point of sale, patients via mobile cloud and payers clinical and pharmacy staff engagement through their workflows. Among the valuable results: Lower costs, optimal utilization, better outcomes, higher quality, greater transparency and rigorous compliance. Mr. Ika envisions a $750 billion PBM market long in need of transformation. The five largest PBMs, which manage over 80% of $300 billion in pharmacy benefit spend, provide limited, siloed services using antiquated, legacy platforms. Their lack of holistic vision introduces an additional $350 billion of avoidable drug-impacted medical costs into U.S. health care. In addition, $100 billion in poorly managed “buy and bill” specialty drug spend needs to be converted to an “authorize and manage” model. More than 15 years ago, Mr. Ika recognized a similar transformational opportunity in health insurance. Industry insiders, challenged to reduce administrative costs by 30% and avoidable medical costs by 20%, saw the goals as unachievable. Mired in paper-based processes, the industry also struggled with a myriad of fragmented, inflexible, and expensive legacy systems. Mr. Ika responded to this opportunity with ikaSystems, an enterprise payer-platform company. Disrupting obsolete paradigms, he delivered unprecedented change long before passage of the Patient Protection and Affordable Care Act. The ikaSystems platform decreased administrative costs for many health insurers by as much as 50% and significantly reduced avoidable medical costs. With these results, ikaSystems raised more than $140mm capital from Providence Equity and Essex Woodland Ventures. Known for building and inspiring world-class teams, Mr. Ika takes a hands-on approach to ensure his clients’ success. Over the years, healthcare industry leaders have come to rely on his vision and talent for creating enterprise platforms that radically disrupt legacy business paradigms and deliver significant value. Mr. Ika has a master’s degree in environmental engineering from Old Dominion University and worked as a research scientist at Harvard University prior to his entrepreneurial career.
Follow Ravi Ika:
About RxAdvance: RxAdvance, a national full service PBM, leverages disruptive Collaborative PBM Cloud™ to manage standard & specialty drug benefits.
CEO of Vir Biotechnology
George A. Scangos, Ph.D., is the chief executive officer and a member of the Board of Directors of VIR. Previously, he was the chief executive officer and a member of the board of directors of Biogen since July 2010. From 1996 to July 2010, Dr. Scangos served as the president and chief executive officer of Exelixis, Inc., a drug discovery and development company, where he continues to serve on the board. From 1993 to 1996, Dr. Scangos served as president of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer’s biological products. Before joining Bayer in 1987, Dr. Scangos was a professor of biology at Johns Hopkins University, where he is still an adjunct professor. Dr. Scangos served as non-executive chairman of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 to July 2010 and was a director of the company from 2003 to July 2010. He currently serves on the Boards of Directors of Agilent, Exelixis, and Decibel Therapeutics.
Follow George Scangos:
About Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases.
Founder & CEO of Embark
Ryan Boyko is the CEO and co-founder of Embark Veterinary, Inc. Since graduating from Harvard in 2005 with a BA in Computer Science, he has used Big Data analyses to further scientific research and business development across a number of fields before targeting consumer canine genetics. After receiving an MS in Ecology and MA in Evolutionary Anthropology from the University of California at Davis, he worked to develop Big Data retail consulting analytics for Oliver Wyman. He is currently also completing a PhD in the Epidemiology of Microbial Diseases at the Yale School of Public Health. Since 2007, he has worked part time with his brother Adam on understanding the history and genetics of the domestic dog. This work has sent him to over three dozen countries and led to several publications. He has now chosen to pursue advancing canine health and genetic understanding full-time, building a company to put develop and promote the health and genetic understanding of man’s best friend.
Follow Ryan Boyko:
About Embark: Embark offers dog DNA testing that ends preventable diseases in dogs.
Co-Founder and CEO of Vicarious Surgical
Follow Adam Sachs:
About Vicarious Surgical: Vicarious Surgical improves the lives of patients and surgeons by giving access to high quality care through the use of surgical robotics.
Founder & CEO of CareAcademy
Helen is CEO and Co-Founder at CareAcademy.com. She is passionate about caregiving and the impact that the right caregiver can have on families. Prior to this, Helen had worked with Teach for America, Boston Public Schools, and Pearson Education as well as a number of companies focused on caregiving issues. Care Academy was born out of her own experience as a nanny and she hopes that sittercycle.com is a place to continuously learn and share with current and future nannies. She holds a B.A. from the University of Notre Dame and an EdM. from the Harvard Graduate School of Education.
Follow Helen Adeosun:
About CareAcademy: Online training empowering senior care professionals to deliver the highest caliber of service and improve the lives of older adults.
CEO & Co-Founder of Current Health
I left school at the age of 16 and graduated with a Masters in Computer Science at age 21. At 20, I set up my first company, Dizeo – this was in social networking for children. This failed in 2011 but the experience taught me some of the most valuable lessons of my life. Around the same time, I was spending time in hospitals due to an unwell relative. I decided to go to medical school as a result in 2012. In 2014, I founded snap40 as a direct result of my experiences working in hospital. I was part of the care of patients who had deteriorated avoidably because the warning signs were detected late. I wanted a world where myself and my family would be treated preventatively at the earliest possible point. snap40 prevent illness by automatically detecting those at high risk. We’re a software company who uses our own wearable device, worn on the upper arm of the patient, to continuously monitor them. We then do predictive analytics to identify the patient who needs medical attention most and bring healthcare to them, far earlier. Please get in touch! E-mail: [email protected]
Follow Christopher McCann:
About Current Health: We help healthcare reduce risk & cost by monitoring, managing and engaging patients at home.
Founder and CEO of Keto and Co
Ted is the Founder and CEO of Keto and Co / Sated. Formerly cofounder and CTO of SittingAround.com
Follow Ted Tieken:
About Keto and Co, SittingAround: Keto and Co makes a growing line of ultra-low carb, ketogenic foods.
Co-Founder & Chief Executive Officer of Iora Health
Rushika Fernandopulle is Co-founder and CEO at Iora Health
Follow Rushika Fernandopulle:
About Health Rosetta Group, Iora Health: Iora Health is a healthcare company that helps patients manage their health and navigate the healthcare system.
President and Founding CEO of Moderna Therapeutics
Stephane joined Flagship Ventures in 2013 and focuses on providing strategic counsel and support to portfolio companies. He is President and Founding Chief Executive Officer of Moderna Therapeutics, a Flagship VentureLabs – founded company. He is also executive chairman of the board for portfolio company BG Medicine, Inc. Stephane was previously CEO of bioMerieux, a world leader in the diagnostics industry. During his five years leading the company, he accelerated the company’s sales growth rate, enhanced its position as a global leader in clinical microbiology and re-accelerated its immunoassay franchise by focusing on high medical value biomarkers. During that time, the company’s market capitalization nearly doubled despite the financial crisis. Prior to his time at bioMerieux, Stephane was Managing Director of Eli Lilly in Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain at Eli Lilly in Indianapolis. He holds a Master of Engineering from Ecole Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School. Stéphane was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best CEO for Investor Relations in France in 2009 and was ranked #1 CEO in the Biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL Study.
Follow Stephane Bancel:
About Flagship Pioneering, Moderna Therapeutics, Qiagen: Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Daniel R. Omstead
President and Chief Executive Officer of Tekla Capital Management
Daniel R. Omstead, Ph.D., is President and Chief Executive Officer of Tekla Capital Management, LLC. He is also President of H&Q Lifesciences Investors and H&Q Healthcare Investors, two NYSE listed closed-end mutual funds that make venture and public equity investments principally in small, emerging healthcare-related companies. Prior to joining Tekla, Dan was President and CEO of Reprogenesis, Inc. a private development stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc a public biotech company that developed CNS therapies. Prior to entering the biotech industry, Dan was employed for fourteen years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson and Johnson and at Merck Sharpe and Dohme Research Laboratories, a division Merck and Company, Inc. While at J&J, Dan participated in the development of Orthoclone OKT3™, Eprex™/Procrit™ and other biological products. While at Merck, he worked on the development of Recombivax™, Mefoxin™, Heartguard™ and other traditional drug products. Dan holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.
Follow Daniel R. Omstead:
About Tekla Capital Management: Tekla Capital Management is an investment adviser.
CEO & Co-Founder of Cake
Suelin Chen is the CEO and co-founder of Cake (joincake.com), an online platform for advance care and end-of-life planning that is used by companies including Blue Cross Blue Shield of MA, Harvard Pilgrim, Liberty Mutual, and Massachusetts General Hospital. Suelin earned her BS and PhD from MIT, where she engineered new medical imaging technologies at a translational research lab at MGH. She served as the director of The Lab at Harvard, where she worked with student entrepreneurs and researchers at the Wyss Institute to commercialize their ideas. Suelin then worked as a transaction advisor to healthcare companies at IMS Health Capital before starting Cake.
Follow Suelin Chen:
About Cake: Cake is the world’s largest platform for helping people navigate end-of-life.
Co-founder, CEO of Clara Health
Evan Ehrenberg is MIT’s youngest ever Ph.D. candidate in the brain and cognitive sciences department, he began the Ph.D. program at the age of 16 after graduating from UC Berkeley in 2010, and is now defending his thesis at the age of 22. Evan has past experience working at Palantir Technologies and other startups, and is an expert in cognitive and computational neuroscience research, with domain experience in human research management and recruitment. Previous: UC Berkeley, Redwood Center for Theoretical Neuroscience, Palantir Technologies
Follow Evan Ehrenberg:
About Clara Health: Clara Health empowers patients to find the right clinical trial for them.
Co-Founder & CEO of Luminopia
Scott Xiao is the Co-Founder & CEO at Luminopia.
Follow Scott Xiao:
About Luminopia: Luminopia is pioneering a new class of treatments for significant neuro-visual disorders.
President & CEO of Intarcia Therapeutics
Follow Kurt Graves:
About Intarcia Therapeutics: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Founder and CEO of Zus Health
Jonathan Bush is the CEO and Founder of Zus Health. He is also the Chief Executive Officer, President, and Chairman of the Board of Directors. Mr. Bush co-founded athenahealth, Inc. in 1997 and has been a director since our inception. Prior to joining the Company, Mr. Bush served as an EMT for the City of New Orleans, was trained as a medic in the U.S. Army, and worked as a management consultant with Booz Allen & Hamilton. Mr. Bush obtained a Bachelor of Arts in the College of Social Studies from Wesleyan University and an M.B.A. from Harvard Business School.
Follow Jonathan Bush:
About Firefly Health, Zus Health: Zus Health helps a new wave of healthcare builders to create technologies and services without the usual blockers.
CEO of BIOMx
Jonathan Solomon is the CEO of BiomX.
Follow Jonathan Solomon:
About BIOMx: BIOMx is a microbiome therapeutics company developing synbio phage therapies to eradicate harmful bacteria in chronic diseases.
CEO of Olink
As President and CEO of Olink Proteomics the vision and goal is to facilitate and implement Precision Medicine via discovery and development of validated protein targets to identify smaller protein signatures for e.g. stratification and prediction and advance them in to clinical decision making. Jon is an entrepreneur and has spent the last 25 years in various biotech start-up companies, developing and commercializing medical devices and biotech drugs. He studied economy at the Uppsala University and has an MBA from IHM Business school in Stockholm. Jon was part of a small team that started Swedens latest most successful biotech which grew to 800 people around the world, market leader in its segment, went public and eventually sold to Galderma. Prior to joining Olink Proteomics as President and CEO he ran a small orphan drug company developing two drugs into late stage clinical trials through the FDA with novel treatments for hyperoxaluria.
Follow Jon Heimer:
About Olink: Olink develops ground-breaking technologies for biomolecular analysis.
Founder & Chief Executive Officer of Idenix Pharmaceuticals
Jean-Pierre Sommadossi is a veteran in the field of biotechnology. Jean Sommadossi was the Principal Founder of Idenix Pharmaceuticals, Inc (NASDAQ: IDIX) and a co-Founder of Pharmasset, Inc (NASDAQ: VRUS), and served as Chairman and Chief Executive Officer of Idenix Pharmaceuticals from November 2000 to November 2010. From 1998 to November 2000, Jean Sommadossi has served as Chairman of the Board of Directors and then as Executive President and Chief Scientific Officer. Under his leadership, Idenix has raised more than $450 million in private and public equity financings and entered into multiple strategic partnerships, including those with Sumitomo and GlaxoSmithKline (GSK) as well as a landmark biotechpharma transaction with Novartis Pharma AG in 2003. Prior to founding Idenix, Jean Sommadossi was on the Faculty of The University of Alabama at Birmingham School of Medicine since March 1985. He has served as a Professor of Pharmacology, Toxicology and Clinical Pharmacology as well as an Associate Director of both the Center for AIDS Research and The Liver Center from June 1992 to November 2000. Jean Sommadossi has authored over 180 peer-reviewed publications and holds more than 50 US patents related to the treatment of Cancer and Infectious Diseases. Jean Sommadossi has earned his Pharm.D. and Ph.D. in Pharmacology degrees from the University of Marseilles in France. He was a postdoctoral Fogarty Fellow at the National Cancer Institute and the Medical College of Virginia and a recipient of a Faculty Award from The American Cancer Society. Jean Sommadossi currently is a Senior Advisor to PureTech Ventures. Jean Sommadossi was recently named to the Therapeutics Advisory Council of Harvard Medical School.
Follow Jean Sommadossi:
About Atea Pharmaceuticals, Idenix Pharmaceuticals: Idenix Pharmaceuticals is focused on the discovery and development of drugs for the treatment of human viral diseases.
Chief Executive Officer of ZOLL Medical Corporation
Jonathan Rennert was named Chief Executive Officer of ZOLL in April 2016. Since joining ZOLL in 2008 as President, he has led the company to become the global leader in external defibrillation, diversified the product portfolio through the addition of transport ventilators and intrathoracic pressure regulation (IPR) therapy, and has overseen the establishment of Asahi Kasei ZOLL Medical, ZOLL’s Japanese subsidiary. Prior to joining ZOLL, Jonathan Rennert led the analytical instruments business at PerkinElmer, Inc., and earlier in his career, held manufacturing and engineering leadership positions with United Technologies and General Electric. Jonathan Rennert holds master’s degrees in management and mechanical engineering from the Massachusetts Institute of Technology (MIT) and a bachelor’s degree in mechanical and aerospace engineering from Princeton University.
Follow Jonathan Rennert:
About ZOLL Medical Corporation: ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions.
CEO & Founder of DoseSpot
Follow Andrew Needleman:
About Claricode, DoseSpot: E-Prescribing Integration Services
Founder and CEO of Replimune Group
Robert Coffin is co-founder and CEO of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in the US. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.
Follow Robert Coffin:
About Replimune Group: Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
Co-Founder, Chief Executive Officer & President of Amwell
Roy Schoenberg M.D., MPH founded American Well Inc. and serves as Chief Executive Officer and President of its American Well Systems. Roy Schoenberg founded Carekey, Inc. and served as its President. He served as a Senior Vice President and Chief Internet Solutions Officer at TriZetto, following its acquisition of CareKey in December 2005. He served as Senior Associate of the Center for Clinical Computing, Beth Israel Deaconess Medical Center, Harvard Medical School. He serves as a Director of American Well Corporation. Roy Schoenberg is a frequent speaker at the American Medical Informatics Association and other conferences. He has published a number of scientific papers in leading journals. In 1998, he joined the Harvard-MIT Fellowship Program in Clinical Informatics and earned an additional MPH in Healthcare Management from the Harvard School of Public Health. Roy Schoenberg completed his Medical Training (MD) at the Hebrew University of Jerusalem.
Follow Roy Schoenberg:
About Amwell: Amwell is a telehealth platform that provides its patients with more affordable, higher quality health care.
Co-Founder, Chairman, and Chief Executive Officer of Amwell
do serves as the Chairman and CEO of American Well Corporation and oversees the company’s corporate strategy. Ido has a lengthy track record of successfully leading technology companies in the healthcare field. In 1996, together with Phyllis Gotlib, he co-founded iMDSoft, a provider of enterprise software that automates hospital critical care units. He grew the company into a market leader with a large multi-national install base in the U.S., Europe, and East Asia. In 2001, Ido joined CareKey Inc. as Chief Executive Officer and took the company through its acquisition by the TriZetto group. Ido served as TriZetto’s Chief Business Strategy Officer until his departure in the summer of 2006. Ido received his MD from the Sackler School of Medicine.
Follow Ido Schoenberg:
About Amwell: Amwell is a telehealth platform that provides its patients with more affordable, higher quality health care.
Co-Founder & CEO of AVA
Ian Brady is the Chief Executive Officer at Hologram Sciences.
Follow Ian Brady:
About AVA, Great Marsh Brewing Company, Hologram Sciences, Plenty: AVA is a personalized, data-driven nutritional coaching solution.
CEO and Co-founder of HumanFirst
Follow Andrea Coravos:
About HumanFirst: HumanFirst enables safe, effective, and equitable healthcare operations at home.
CEO of PillPack
TJ Parker is the Co-Founder and CEO of PillPack. He is also a Board Member of RxArt. Mr. Parker is a former Pharmacist at NEPS and Founding Organizer at Hacking Medicine at MIT.
Follow TJ Parker:
About PillPack: PillPack is a full-service pharmacy that sorts medication by dose and offers door-to-door delivery.
Co-Founder and Chief Executive Officer of IntelyCare
David Coppins is co-founder and CEO of IntelyCare, the intelligent workforce management solution for post-acute healthcare facilities. Prior to starting IntelyCare, David served as president of Virgin Pulse, part of Sir Richard Branson’s Virgin Group. Before Virgin Pulse, David co-founded the college savings company Upromise in 1999. After Sallie Mae bought Upromise for $300M in 2006, David remained with the company and was later named CEO. Earlier in his career, David held various roles in business consulting and private equity at companies including Monitor Deloitte and Monitor Clipper Partners. David has a bachelor’s degree in business management from Brigham Young University.
Follow David Coppins:
About IntelyCare, Virgin Pulse: IntelyCare is revolutionizing healthcare staffing, scheduling, and training by offering an enterprise workforce management platform.
Co Founder & CEO of Mightier
Craig Lund is a Co-Founder and Chief Executive Officer at Mightier.
Follow Craig Lund:
About Mightier: Mightier is a gaming platform and family program scientifically-proven to help kids regulate their emotions.
Founder/CEO of Stynt
Follow Alex Adeli:
About Stynt: Simplifying healthcare staffing to enhance the quality of patient care.
Founder and CEO of MD Ally
As the child of a volunteer EMT, Shanel Fields was inspired by her father’s experiences as a first responder to launch a healthcare technology company in the 911 space that focuses on ensuring the appropriate use of finite emergency resources and improving long-term patient outcomes. In 2018, she leveraged her mobile and healthcare technology expertise to launch MD Ally, an EMS telemedicine platform that enables collaborative partnerships between public safety and provider organizations for large-scale mobile integrated healthcare initiatives. Shanel has found that driving innovation in the 911 space has fulfilled her desire to positively impact the world around her and improve the health of all citizens, particularly when they’re at their most vulnerable moments. Prior to launching MD Ally, Shanel attended Wharton Business School where she majored in Healthcare Management, Entrepreneurship and Innovation, as well as worked alongside life-long EMS researchers to study patient ER utilization and first responder advocacy. For more than a decade, she’s worked for innovative companies like AT&T and athenahealth, where she has scaled and led impact-focused growth teams focused on enterprise health systems, payers, and independent health entities.
Follow Shanel Fields:
About MD Ally: MD Ally is a telehealth company that enables a virtual response tier for 9-1-1.
President & CEO of Partners HealthCare
David F. Torchiana is Member of the Board of Directors, President & CEO at Partners HealthCare.
Follow David Torchiana:
About Partners HealthCare: Partners HealthCare was founded in 1994 by Brigham and Women’s Hospital and Massachusetts General Hospital.
Chief Executive Officer of Admetsys
Follow Jeff Valk:
About Admetsys: For people at diabetic risk, glucose control is at its most crucial while in hospital or surgery.
Founder, CEO of PureTech Health
Daphne Zohar is the founder and managing partner of PureTech, a technology development company tackling tomorrow’s biggest healthcare challenges. Ms. Zohar was recognized by Fierce Biotech as one of the “Top 10 Women in Biotech,” BioWorld as one of 28 leaders predicted to be the “movers and shakers” of the biotechnology industry over the next twenty years, and by the Boston Globe as one of the “Top 15 Innovators.” A successful entrepreneur, Ms. Zohar created PureTech and assembled a leading team to help implement her vision for the firm. She sits on the Boards of Directors of PureTech, Enlight (a cross disciplinary consortium of leading healthcare and pharma companies), Follica Inc., Akili Interactive Labs, Vedanta Bioscience, Mandara Sciences, Karuna Pharmaceuticals, and Tal Medical. She also sits on the Technology Development Fund Advisory Board at Children’s Hospital Boston and is an Editorial Advisor to Xconomy, a national technology news blog.
Follow Daphne Zohar:
About PureTech Health: PureTech Health is a bio pharma company and pushes the boundaries of medicine and changing and converging healthcare ecosystem.
President & CEO of TransMedics
Dr. Waleed Hassanein is president , CEO and director of TransMedics, Inc. He founded the company in August, 1998. As an experienced medical device executive, Waleed brings more than eleven years of experience in establishing and leading executive teams through the clinical development, market launch and commercial rollout of the company’s breakthrough Organ Care System (OCS™) technology in the European and US markets. Waleed has successfully raised >$120 million of private equity capital to develop and commercialize the OCS™ technology and has established world-class clinical advocates for the OCS™ technology world-wide from the key opinion leaders in organ transplantation. Waleed received his M.D. from Georgetown University where he also completed two years of General Surgery residency. He completed his pre-medical education from University of London and Cairo University School of Medicine.
Follow Waleed Hassanein:
About TransMedics: Transmedics is a medical device company involved in the design and production of transplant devices.
Founder & CEO of Par8o
Daniel Palestrant studied at Johns Hopkins, Duke University, and Harvard Medical School. He co-founded SERMO, the largest online physician community in the world, which was acquired in 2013.
Follow Daniel Palestrant:
About Par8o: The current healthcare crisis is a uniquely American challenge and ultimately will be solved with a uniquely American solution.
Founder, President & CEO of Avrobio
Geoff is a pioneer in cell and gene therapy with a track record of successful leadership at innovative biotechs. He is the former CEO of Organogenesis Inc., the world’s leading cell therapy company. During his tenure at the helm, the company treated 1 million patients with living cell therapies, received the first approval of an allogeneic cell therapy from the FDA’s Center for Biologics Evaluation and Research and led the field of regenerative medicine. Geoff is also the founding CEO of eGenesis, a biotech dedicated to applying CRISPR Cas-9 gene editing to xenotransplantation. Earlier in his career, Geoff spent 11 years at Novartis in senior leadership positions within the global transplantation and immunology franchise. Geoff sits on the boards of Talaris Therapeutics and Satellos Bioscience. Past activities include chairman of the board of MassBio, chairman of the board of the Alliance of Regenerative Medicine, and a member of the advisory council to the Health Policy Commission for Massachusetts.
Follow Geoff MacKay:
About Atlas Venture, Avrobio: Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Elisabet de los Pinos
Founder and CEO of Aura Biosciences
Follow Elisabet de los Pinos:
About Aura Biosciences: Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Founder & CEO of ORIG3N
Robin Y Smith is the Founder and CEO of ORIG3N, a biotechnology company developing a breakthrough disease-modeling platform targeting rare genetically inherited diseases and DNA testing solutions for Health and Wellness. Visit: www.orig3n.com
Follow Robin Smith:
About ORIG3N: ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Jeffrey D. Wager
Co-Founder, Chairman & CEO of EnBiotix
Follow Jeffrey D. Wager:
About EnBiotix, Proterris: EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.
Founder & CEO of iMotions A/S
Peter Hartzbech passion is global entrepreneurship and building companies. Driven by a desire to make a difference in the world, he embarked upon his entrepreneurial career by starting his first venture at the age of 25. Prior to founding iMotions, he worked in Ernst & Young Denmark and Venture Cup Denmark, where he advised start-up companies on business plans, strategic and financial issues. In December 2006, Peter was appointed by Red Herring Magazine as Top 25 under 35, where the Magazine appoints Notable Entrepreneurs under 35. Peter’s positive attitude and global vision have been the main driving forces behind iMotions’ rapid growth and expansion.
Follow Peter Hartzbech:
About iMotions A/S: iMotions A/S develops and provides biometric platforms, neuromarketing, psychology, VR, and engineering solutions.
President & CEO of New Balance
Joe Preston is the President and CEO at New Balance.
Follow Joe Preston:
About New Balance: New Balance is an American multinational corporation based in the Brighton neighborhood of Boston.
Founder and CEO of OM1
Rich Gliklich is the Founder and CEO at OM1.
Follow Rich Gliklich:
About Cyft, OM1: OM1 is a healthcare technology company that leverages real-world clinical data for medical research and personalized medicine.
Keith M. Gottesdiener
Chief Executive Officer of Motus Therapeutics
Keith Gottesdiener is the President & CEO at Prime Medicine, Inc..
Follow Keith M. Gottesdiener:
About Motus Therapeutics, Prime Medicine: Motus Therapeutics is a biotechnology company developing peptide therapeutics for the treatment of metabolic diseases.
CEO of Alnylam Pharmaceuticals
Chief Executive Officer & Director at Alnylam Pharmaceuticals.
Follow John Maraganore:
About Alnylam Pharmaceuticals, Alnylam Pharmaceuticals, Third Rock Ventures: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Founder & CEO of Marigold Health
Follow Shrenik Jain:
About Marigold Health: Marigold Health uses chat support groups to make substance use treatment more engaging and personalized for vulnerable populations.
Co-founder and CEO of PharmaCCX
Nathan was previously co-founder and CEO of PharmaSecure where he helped accelerate adoption of serialization as the standard in global pharmaceutical supply chain. Nathan is a graduate of Dartmouth College.
Follow Nathan Sigworth:
About PharmaCCX: We are a one-stop-shop for pharmaceutical companies and payers to negotiate, price, settle, and manage complex deals more efficiently.
CEO of Medsix
Nikin believes in using technology and leveraging existing resources to challenge the status-quo and impact lives. Nikin discovered he had a talent for electronics and started working at a lab affiliated with the Border Security Force in India at 9 y/o. He successfully piloted projects on agricultural management, anti-train collision, smart homes and got a honorable citation from the President of India. In his role as the President of WISE, Nikin improved STEM education at low-income schools in India through an innovative experiential education curriculum. Over the summer of 2015, he conducted an impact assessment of the non-profit with a research grant from Northeastern which helped WISE go national. Nikin got a full scholarship to attend Northeastern at 16 y/o. After the Harvard-MIT hackathon on iCorruption, he worked at Harvard Law School with Prof. Lawrence Lessig to research ways to reduce bias in academia. At HackingEDU 2015, he co-founded ITAP, a social enterprise that creates IT apprenticeship program for disadvantaged youth in the Bay Area. ITAP got selected for the Clinton Global Initiative University 2016, again in 2017, shortlisted for their Innovation Fund and secured a grant from Northeastern. For the latter half of 2016, Nikin was a Visiting Innovation Fellow at John Hancock’s Lab of Forward Thinking. In early 2017, he helped set up the world’s first open innovation platform with IoT at Northeastern. At MIT HackingMedicine, his team won two prizes and he co-founded Medsix, a medtech startup focused on post operative recovery management. After graduating, Nikin worked on commercializing the world’s first nanomaterial-based ion detector at Guardion and is an alumnae of the Techstars-US Air Force accelerator. He raised $250k for Medsix and now works there full-time. He enjoys reading, listening to podcasts, networking and being a mentor to millennial entrepreneurs.
Follow Nikin Tharan:
About Medsix: Novel wound drainage monitoring sensors + predictive tools for better patient outcomes
Founder, President & CEO of Walden Behavioral Care
Stuart Koman, Ph.D. is a founder and the Chief Executive of Walden Behavioral Care and its non-profit sister corporation, the Walden Center for Education and Research. Dr. Koman is a veteran health care manager with more than 30 years of experience leading and developing several behavioral health care companies. While all of these companies have become successful businesses under his leadership, Dr. Koman attributes much of this success to another common theme: they have all taken seriously their mission of providing innovative, compassionate and coordinated services to previously under served populations and families. Walden Behavioral Care is the most recent example as it has quickly become the leading provider of services for individuals with eating disorders in New England through its multi-level, multi-site system of care. In the nine year period 2003-2012, Walden has become a state of the art system of care providing some 40,000 service units annually at its primary campus in Waltham (MA) and satellite centers in Braintree (MA), Worcester (MA), Northampton (MA) and South Windsor, Connecticut. Dr. Koman began his professional career in 1985 when he was appointed senior clinician and then Director of Adolescent Programs at Charles River Hospital (CRH) in Wellesley, MA. Over the next 10 years (1985 to 1996), he led two companies in achieving significant clinical and business outcomes. The first company, Charles River Management (CRHM), a subsidiary of CRH, grew out of the work of Dr. Koman and others in developing innovative treatment models for adolescents in hospital settings. Dr. Koman and his colleagues were among the first to recognize the central importance of the family in treatment program design. Many of these and related ideas were published in the Handbook of Adolescents and Family Therapy, an effort in which Dr. Koman wrote several chapters and served as co-editor. In 1990, Dr. Koman co-founded the managed health care company, Choate Health Systems, Inc. (CHSI). Similar to the approach at Charles River, Choate provided integrated delivery of behavioral health care through a full continuum of treatment services operating under one administration. As this model proved highly adaptive in the emerging world of managed care, Choate expanded rapidly, and this led to the formation of Choate Health Management, Inc. (CHMI) and Choate Psychiatric Associates, P.C. (CPA). Having successfully managed the transition in health care reimbursement approaches, Dr. Koman was asked to assist the profession of psychology to do the same and subsequently served on the Governing Board of the American Psychological Association’s practice division from 1992-2000. After leaving Choate in 1995, Dr. Koman started Koman Associates, a firm that focuses on leaders and leadership issues in government, health care and business. At the same time, Dr. Koman served as Senior Clinical Adviser for Public Consulting Group providing strategic planning and systems re-engineering to state agencies throughout the United States. Dr. Koman continues his involvement with both of these organizations albeit on a much reduced basis once Walden was established in 2003. Dr. Koman earned his Bachelor of Science degree from Trinity College and his Ph.D. from Duke University.
Follow Stuart Koman:
About Walden Behavioral Care: Walden Behavioral Care, a Waltham, Mass.-based provider of behavioral health services for individuals with eating disorders.
Co-founder & CEO of Labfront
At kiipo, Chris utilizes his experience in product development from his work on several products starting with his work at HTC on the Dynamical Biomarkers Group’s entry into the Tricorder XPRIZE. Since then, he managed the design and engineering effort in the creation of Ethiopia’s first Emergency Medical System. Although his background is electrical and software engineering, he is passionate about designing for social impact. Prior to his time at HTC, he spent 6 months as a volunteer in Northern Thailand where he taught technology skills to underprivileged children as a ladder out of poverty. Chris also worked with local nonprofits to improve their business models. Thailand was his first foray into sustainable social impact, since then he’s done work in Ethiopia, China, and Taiwan.
Follow Chris Peng:
About Labfront: Labfront elevates your research findings by simplifying physiological data collection and management.
Founder and CEO of Valo Health
David Berry, M.D., PhD., is an American inventor, entrepreneur, venture capitalist and CEO. Berry has co-founded and helped build over 10 companies in life sciences, technology, and sustainability. In 2007, he was named as the Innovator of the Year from the MIT Technology Review TR35 list of one of the top 35 innovators in the world under the age of 35. He was selected as a 2014 Young Global Leader by the World Economic Forum. In 2007, Berry founded Joule Unlimited, which is developing Solar Fuels—drop-in fuels produced directly from the sun. Berry served as President and CEO of the company through April 2009, and currently serves on the Board of Directors. Joule is pioneering solar fuels through a new technology that coverts sunlight, carbon dioxide, and salt water into drop-in fuels for prices as low as $20. In March 2010 and again in March 2011, Joule was named by Technology Review as one of the 50 Most Innovative Companies. Joule was named as one of the 10 most important emerging technologies in 2011. Joule’s unique and innovative approach to fuels led to its being named a Technology Pioneer by the World Economic Forum in 2012 and to its receiving the Silver Medal in the 2011 Wall Street Journal Technology Innovation Awards. Joule’s technology has now been successfully scaled to a demonstration facility, and the company has announced a commercial partnership with Audi. Berry has been recognized multiple times as one of the top people in bioenergy by Biofuels Digest. In 2009, Berry founded Pronutria, which is pioneering a new approach to unlock the vast untapped therapeutic potential of proteins in the diet. Berry served as President and CEO through March 2012. Pronutria has built a proprietary database that contains over 1 billion food proteins, and leverages 40 years of clinical data that validates the pharmacological activity of particular amino acid combinations to identify proteins that, when delivered orally, act as prodrugs. The protein delivery form allows for of important drug-like properties including pharmacokinetic control and improvement of physiochemical features. Pronutria has advanced two of its ProNutrein™ into clinical trials. In 2011, Berry founded Seres Health, a company that develops a new class of therapeutics based on insights into the biology of the human microbiome. Seres Health has developed a new approach to functionally assess the changes of the microbiome associated with disease, and identifies a consortia of organisms that can catalyze a shift to health. Seres has advanced is lead into the clinic for recurrent C. difficile. In 2005, Berry co-founded LS9, with Chris Somerville, Jay Keasling, and George M. Church, which uses synthetic biology to engineer microorganisms to covert sustainable, plant-based materials into low-carbon fuels and chemicals. LS9 has successfully built on technologies he invented with other co-founders to produce a scalable platform for renewable fules and chemicals. This technology was successfully scaled to a fully operational 135,000L facility in Okeechobee, Florida. The impact and importance of LS9’s technology led to its being named a Technology Pioneer by the World Economic Forum in 2008 and its being awarded the Presidential Green Chemistry Challenge Award in 2010, the U.S. Environmental Protection Agency’s highest environmental honor. LS9 was acquired by Renewable Energy Group in 2014. Berry joined Flagship Ventures, a Cambridge, Massachusetts based venture capital firm that invests in and founds companies in healthcare and sustainability, in 2005 where he is a Partner. Berry has been described “a rising star of the Boston-area venture capital scene,” and “one of the most brilliant thinkers.” Berry serves on the Board of Directors of Joule Unlimited, Seres Health, Pronutria, Eleven Biotherapeutics (NASDAQ: EBIO), and Symbiota. Berry has been an author of 14 scientific papers and over 60 patent applications.
Follow David Berry:
About Axcella, Evelo Biosciences, Flagship Pioneering, Hackley School, Indigo, Joule Unlimited Technologies, Omega Therapeutics, Seres Therapeutics, Seres Therapeutics, Valo Health: Valo Health uses human-centric data and machine learning-anchored computation to transform the drug discovery and development process.
Founder & CEO of FOLX Health
A.G. is a co-founder of Humedica and serves as Chief Product Officer, Optum Analytics. Prior to Humedica, she was a Director at Leerink Swann, a leading health care investment bank. Previously, A.G. co-founded the Institute for Health Metrics (IHM). In 2000, she co-founded PrivaSource, which focused on the de-identification of health data. A.G. also served as Chair of the Massachusetts Work Group on the Privacy of Medical Records and was the primary drafter of the Massachusetts “Act to Protect the Privacy of Medical Records.” A.G. teaches ethics with Professor Marc Roberts at the Harvard School of Public Health. She received her MPH from Harvard University, her JD from the University of Connecticut, and her bachelor’s degree from Yale University.
Follow Agneta Breitenstein:
About FOLX Health: FOLX Health provides digital health care services designed for the LGBTQIA+ community.
Founder & CEO of karmadata
Follow Sean Power:
About karmadata, Power Fund Partners, PrescribeWellness, WIRB-Copernicus Group: Healthcare (Big) Data Simplified
CEO of Goodpath
CEO & CoFounder of Goodpath CEO & CoFounder at Trumpit CPO, Vp Engineering and Co-Founder at HeyWire
Follow Bill Gianoukos:
About Goodpath: Goodpath is a telehealth startup focused on improve helping people managing common health conditions.
CEO of Pillo Health
Emanuele Musini is the CEO and Co-Founder of Pillo Health.
Follow Emanuele Musini:
About Pillo Health: Pillo Health is a healthcare solutions provider that empowers organizations to deliver better care into the home.
Co-Founder & CEO of Worthright
Aaron is the Co-Founder and CEO of Worthright.
Follow Aaron O’Hearn:
About Worthright: Worthright is a family of aging adults plan.
Chief Executive Officer of ReviveMed
Founder and CEO at ReviveMed, experienced engineer and entrepreneur with a Ph.D. in Biological Engineering from MIT. During her PhD at MIT, Leila Pirhaji developed a pioneering machine-learning technology, which translates data from small molecules or metabolites into therapeutic solutions and was published in Nature Methods. Leila Pirhaji founded ReviveMed Startup Company to commercializes this technology, and enable developing the right therapeutics for the right patients by leveraging machine-learning and metabolomics.
Follow Leila Pirhaji:
About ReviveMed: ReviveMed is a precision-medicine platform that leverages the data from small molecules or metabolites.
CEO of Centaur Labs
Follow Erik Duhaime:
About Centaur Labs: Labeling medical images at scale
Founder & CEO of Sober Grid
Follow Beau Mann:
About Sober Grid: Sober Grid is a digital health application focused on creating mobile communities that engage people into chronic disease management.
Founder & CEO of QMedic
Sombit brings 10 years of experience in Web/Mobile/Wearable UX, strategy, product management, marketing, and business development to QMedic. Previously, he conceived, designed, and launched an obesity management and telemedicine application in partnership with one of the world’s leading hospitals. He has been invited to speak at numerous conferences on mobile health and healthy aging, including AARP, Health 2.0, Aging 2.0, the Cleveland Clinic Summit, and Athenahealth’s More Disruption Please. In 2013, Sombit was selected as a TEDMED Innovation Scholar and 1 of 14 Emerging Innovators by American Express and the Ashoka Foundation. While in graduate school at MIT, Sombit was awarded the Patrick J. McGovern Prize for outstanding contributions to the student community, which included raising over $1M in sponsorships for MIT companies across health, software, and clean technology. He continues to serve as a business mentor to hundreds of executives through the MIT Trust Center for Entrepreneurship and Sloan Fellows programs. Sombit completed his MBA from the MIT Sloan School of Management, an MSc from the London School of Economics, and a BA from Northwestern University.
Follow Sombit Mishra:
About QMedic: QMedic is an intelligent medical alert & routing service to keep care in network and at home.
Joseph K. Jachinowski
President and Chief Executive Officer of Mevion Medical Systems
Joe comes to Mevion Medical Systems with a distinguished 28-year track record of successfully developing products and building companies in the field of radiation therapy for cancer. He was most recently Executive Vice President of Elekta AB, a leading supplier of radiation therapy equipment, and CEO of Elekta Holdings with overall responsibility for all of Elekta’s North American operations. Prior to Elekta, he co-founded IMPAC Medical Systems, and served as its President and CEO through its initial public offering and culminating in its sale to Elekta in 2005. Joe began his career at Varian Medical Systems, where he was responsible for leading the team that developed their innovative linear accelerator products in the 1980s.
Follow Joseph K. Jachinowski:
About Mevion Medical Systems: Mevion Medical Systems develops radiation therapies for the treatment of cancer.
President and CEO of Ablative Solutions
Kate brings 27 years of experience in the Medical Device and Pharmaceutical Industry. Previously she held the position of Vice President, Global Clinical and Medical Affairs at Covidien. She has extensive experience in product development in the CNS space through her time at Aspect Medical Systems and Eli Lilly & Company. Kate first joined NeoSync in 2010, leading the company’s clinical and regulatory activities, and later rejoined as President and CEO in April 2015. She holds a BS degree in both Biology and Psychology from the State University of New York.
Follow Kate Rumrill:
About Ablative Solutions: Ablative Solutions is a medical device firm that offers an alternative to surgical renal denervation for treating hypertension.
Founder & CEO of BeautyLynk
Rica Elysee is the founder and CEO of BeautyLynk, a tech company focused on transforming the beauty industry with technology. Before to devoting her work full time to BeautyLynk, Rica served as a Nonprofit Fundraising Executive for local to national organizations focused on empowerment and education. Aside from her entrepreneurial pursuits she enjoys art, food and laughter.
Follow Modjossorica Elysee:
About BeautyLynk: We bring hair & makeup pros to your doorstep! Convenient and professional services for women of all complexions & hair textures.
Stephen J. Gatto
Chairman and Chief Executive Officer of Entrinsic Bioscience
Stephen J. Gatto founded Myriant’s predecessor company in 2004 and formed Myriant in 2009. He has been involved in the biotechnology industry for over 19 years, founding a successful biofuels company and serving on numerous Presidential, Congressional and US DOE/USDA committees. At BC International (now Verenium), Stephen Gatto, in cooperation with Dr. Lonnie Ingram and the University of Florida, spearheaded the development of novel technology for the commercial production of ethanol from cellulose (patent number 5,000,000). Successful pilot operations led to licensing of the technology to two multinational companies. In 2000 and 2002, Stephen Gatto was appointed by both the Clinton and Bush Administrations to the Biomass Research & Development Technical Advisory Committee. He was also appointed to a Biofuels Ad-hoc Committee chaired by Senator Dianne Feinstein and assisted in the drafting of key aspects of the Energy Policy Act of 2005. Currently, Stephen Gatto is on the board of directors for BIO, the world’s largest biotechnology organization, serving on the Industrial and Environmental (I&E) section governing board.
Follow Stephen J. Gatto:
About Entrinsic Bioscience: Entrinsic Bioscience leverages gold standard science and game-changing amino acid technology.
President & Chief Executive Officer of Lumicell
Follow Kevin Hershberger:
About Lumicell: Lumicell is a biotechnology company that develops and markets image-guided cancer surgery solutions.
Co-Founder & CEO of Ten Percent Happier
Follow Ben Rubin:
About Ten Percent Happier: Ten Percent Happier is a health and wellness platform that offers a simple approach to meditation.
Robert E. Ward
Chairman and Chief Executive Officer of Eloxx
Robert (Bob) E. Ward is the Chairman of the Board and Chief Executive Officer of Eloxx Pharmaceuticals, Inc. (“Eloxx”). He previously served as the Chief Executive Officer and President at Radius Health, Inc. (NASDAQ: RDUS) successfully completing the initial public offering that became the top performing IPO; raised over $780M from private and public sources; achieved FDA approval and launch of the new drug TYMLOStm injection while gaining Fast Track development status for the Elacestrant oncology program. Prior to joining Radius, Robert Ward held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Robert Ward has been a Director of Akari Therapeutics, Plc since October 14, 2016 where he chairs the Governance Committee. He served as a Director of Radius from December 2013 until July 16, 2017. Robert Ward serves as a Director of the Massachusetts High Technology Council. Robert Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from the John Hopkins University School of Medicine.
Follow Robert E. Ward:
About Eloxx: Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates.
Co-Founder and CEO of Medically Home
Rami Karjian co-founded Medically Home and currently serves as the president and COO.
Follow Rami Karjian:
About Medically Home: Medically Home is a tech-enabled clinical enterprise that offers safely-shifting medical care from hospitals to patient homes.
President & CEO of NIDO
Thomas Marchand is a French entrepreneur based in Boston, graduated by ESSEC Business School (Paris). His first company in the private lesson industry was acquired in 2014 by the market leader. Thomas founded then BIOMODEX and served five years as the CEO & Chairman. This medical device company is developing 3d Printed patient-specific anatomical models designed to provide a pre-operative planning solution to physicians in the neurovascular and structural heart space. He raised $20M+ and built a 40 people team in Paris and Boston, including a manufacturing facility in Massachusetts. BIOMODEX counts Medtronic, Stryker, Boston Scientific, and J&J as customers. Thomas recently joined NIDO as the President and CEO, co-founded by Pedro Del Nido, Chairman of cardiovascular surgery at Boston Children Hospital and Professor at Harvard Medical School. NIDO is developing SEPIA, an innovative solution designed to improve epicardial ablation efficiency and, ultimately, cure Ventricular Tachycardia. NIDO is targeting a clearance by the FDA in 2022 and starting commercialization the same year. Thomas has been granted French American Entrepreneur of the year 2016 and is a regular guest at the entrepreneurial finance program at Babson College.
Follow Thomas Marchand:
About NIDO: NIDO is a medical device company developing SEPIA, an Epicardial Ablation Solution for VT.
Founder & CEO of Lumeon
Robbie is the Founder and CEO of Lumeon. An engineer by training, he started the company after first-hand experience of the impact that fragmented care delivery processes have on patient experience. Taking a step back to develop a fresh approach, he built the award-winning Care Pathway Management platform to connect care teams, patients and technology across the care continuum. The platform enables healthcare providers to automate and orchestrate end-to-end processes by creating their own unique pathways. Under Robbie’s leadership, Lumeon has grown to an enterprise-level solution, currently in use by 65 major healthcare providers across the US and Europe managing over six million patient lives. This year, Robbie was named Best Digital Healthcare CEO by GHP Magazine.
Follow Robbie Hughes:
About Lumeon: Lumeon is a digital health company providing management care solutions to the healthcare industry.
Stephen Punzak, MD
CEO & Founder of One Medical Passport, Inc.
Stephen Punzak, M.D., is the founder and CEO of One Medical Passport, Inc., a company that is revolutionizing the pre-op screening process for surgical patients. The One Medical Passport system, first envisioned by Dr. Punzak over a decade ago, has been adopted by hundreds of medical facilities nationwide. This system has streamlined the pre-op and day-of-surgery workflow and resulted in marked improvements in patient safety and convenience. In addition to being the hands-on CEO of a rapidly growing company, Dr. Punzak still practices clinical anesthesia, noting, “this is where many of the company’s best ideas for product development have come from.” Dr. Punzak’s more than 20-year career as an anesthesiologist has included a range of challenges, from performing complex open heart and liver transplant surgeries at the Deaconess Hospital in Boston, to fast-paced ambulatory surgeries, pain management and obstetrical anesthesia. He attained board certification in both anesthesiology and pain management. During his work on the front lines of an anesthesia practice, Dr. Punzak experienced first-hand the inefficiencies and shortcomings of the traditional pre-op process. This experience inspired him to found MWT to make the process much more efficient. Dr. Punzak graduated from the Boston College School of Management in 1983 with a major in finance and a minor in pre-med studies. He was the first graduate of Boston College to simultaneously receive the Scholar of the College Award in Biology and to be chosen as the commencement speaker for the School of Management. Dr. Punzak attended the University of Connecticut School of Medicine and did his residency in anesthesiology at the Brigham and Women’s Hospital in Boston.
Follow Stephen Punzak, MD:
About One Medical Passport, Inc.: One Medical Passport is the convenient, secure online solution that connects patients, medical facilities.
President and CEO of Cyrano Therapeutics
Rick Geoffrion is the President and CEO of Cyrano Therapeutics.
Follow Rick Geoffrion:
About Cyrano Therapeutics, The Mullings Group: Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell.
Co-Founder and CEO of Akili Interactive Labs
Dr. Martucci is a Senior Associate at PureTech Ventures, and is part of the founding team of Akili Interactive Labs, Appeering, and Vedanta Biosciences. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation. Dr. Martucci completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on the rational design of novel allosteric inhibitors for a pathogenic parasite. He led a research project that characterized a potential enzyme drug target and identified two novel chemical scaffolds as potent proof-of-concept compounds for novel antiparasitic therapy. During his graduate work, he received NIH training grants in both Chemical Biology and Parasitology. Dr. Martucci received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.
Follow Eddie Martucci:
About Akili Interactive Labs, PureTech Health: Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games.
Co-founder & CEO of Firefly Health
Andy Ellner is the Co-Founder and CEO of Firefly Health.
Follow Andy Ellner:
About Firefly Health: Firefly Health is a virtual-first health care company that provides primary healthcare services that redefine high-quality patient care.
Founder/CEO of iQuartic
EHR systems and healthcare data expert (in processing and analyzing). Presented at clinical data and systems conferences, and consults healthcare organizations (esp. community based) on leveraging data and systems to advance care quality and financial health.
Follow Ze Jiang:
About iQuartic: iQUARTIC develops cloud-based platforms that eliminate traditional paper-based coding with easy-to-use web programs.
Founder & CEO of Stasis Labs
Michael Maylahn is the Founder & CEO at Stasis Labs.
Follow Michael Maylahn:
About Stasis Labs: Stasis has built a cloud-connected vital signs monitoring system that rescues the 11 million under-monitored patients around the world.
President & CEO of Rhinostics
Cheri Walker currently works as President and Chief Executive Officer at Rhinostics.
Follow Cheri Walker:
About Rhinostics: Rhinostics provides a novel solution of enabling comfortable sample collection, rapid accessioning, and automated cap removal.
CEO & Founder of Palleon Pharmaceuticals
Jim is a Partner on the Morgenthaler Life Sciences Team and invests in companies developing innovative therapeutic products in the biotech and medical device industries. Jim is a co-founder and Chairman at Promedior Pharmaceuticals, a company developing drugs to treat fibrotic diseases such as Idiopathic Pulmonary Fibrosis and Myelofibrosis. Jim is a co-founder and Chairman at Ra Pharmaceuticals, a biotech company developing orally available and cell permeable peptide drugs. Jim was the founding CEO and currently serves as a Board member at SetPoint Medical, a company developing implantable neurostimulation devices to treat inflammatory diseases such as Crohn’s Disease and Rheumatoid Arthritis as an alternative to drug therapy. He is an investor and board member of several other novel biotech and medical device companies, including OncoMed Pharmaceuticals (NASDAQ: OMED), the leader in the field of drugs targeting cancer cell pathways, and Spine Wave, a commercial stage company selling multiple innovative devices for minimally invasive spinal surgery. Jim opened Morgenthaler’s Boston Office in 2005 after spending several years in Silicon Valley. Jim is a graduate of MIT (Bachelors in Mechanical Engineering) and University of Massachusetts (Doctor of Medicine). Jim was a member of the Kauffman Fellows Program, a two-year educational fellowship sponsored by the Kauffman Center for Entrepreneurial Leadership designed to train future venture capitalists and leaders of high growth companies.
Follow Jim Broderick:
About Palleon Pharmaceuticals: Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer.
Co-Founder ,CSO & CEO of Aldatu Biosciences
Iain is responsible for leading the advancement of Aldatu’s pathogen and drug resistance diagnostic technology in addition to guiding the company’s global health strategy. Iain maintains an academic appointment at the Harvard School of Public Health AIDS Initiative. He undertook his post-doctoral training at the Harvard School of Public Health, and the Botswana-Harvard AIDS Institute in Gaborone, Botswana, where he focused on HIV drug resistance. Iain holds a Ph.D. in Pathology – specializing in molecular virology – from the University of Cambridge (2008), an LL.M. in International Law, and a B.Sc. in Virology from the University of Glasgow.
Follow Iain MacLeod:
About Aldatu Biosciences, Harvard T.H. Chan School of Public Health: Aldatu Biosciences is changing infectious disease treatment paradigms through innovative diagnostic solutions.
Founder ,President & CEO of MassVentures
Charles Hipwood is a founder and executive with 20+ years of experience in financial services and technology start-ups (founded Fluent Fintech, STAG Capital Partners and AI Exchange).
Follow Charles Hipwood:
About MassVentures: MassVentures is a venture capital firm focused on supporting Massachusetts-based startups to prosper in their businesses.
Founder & CEO of Swoop
Ron brings 18 Years of President/CEO level experience in high tech and online media. Elwell’s past expereince includes: CEO Goal.com, the leading on-line media company in Football (Soccer). Goal, a global site in 17 languages, became the 10th largest sport site in the world and the largest Football site and was acquired by Perform Media Group. Partner, Bessemer Ventures. As a Partner at Bessemer for 8 years Elwell made a number of investments in advertising, wireless and new media. CEO Octave Communications, a leader in the design and manufacturer of the telecom infrastructure necessary to provide voice and data
Follow Ron Elwell:
About ReefEdge, Swoop: Swoop is a provider of artificial intelligence and machine learning solutions to find, engage, and convert the ideal patient population.
Robert J. Mulroy
Chief Executive Officer of Partner Therapeutics
Bob serves as a director and the Chief Executive Officer of PTx. He has 25 years of experience in the biopharmaceutical and healthcare sector, having led the development of multiple biotech companies and served as an industry consultant. Prior to PTx, he served as a co-founder, CEO, president, and director of Merrimack and a director and CEO of Atlantic Biosciences. He has extensive experience in a complete range of capital transactions, capital raising, global business development, and organizational capability building. Bob earned his undergraduate degree from Stanford and his Masters in Public and Private Management at Yale.
Follow Robert J. Mulroy:
About Partner Therapeutics: PTx is a biopharmaceutical company committed to the development and commercialization of therapies that improve the treatment of cancer.
Bianca Maxwell Harris
Founder & CEO of Skinary
Follow Bianca Maxwell Harris:
About Skinary: an integrative health tracking app for skin
CEO of Antera Therapeutics
Follow Clarence Friedman:
About Antera Therapeutics, Waters Corporation: Antera Therapeutics is creating therapies that will prevent allergy development in children.
Co-Founder and CEO of Xtelligent Media
Sean Brooks serves as the Chief Executive Officer and a Director of Xtelligent Media.
Follow Sean Brooks:
About Xtelligent Media: Xtelligent Media is an online media company focused on information technology in the healthcare industry.